AR086914A1 - Procedimientos de purificacion de formas nativas o mutantes de la toxina difterica - Google Patents
Procedimientos de purificacion de formas nativas o mutantes de la toxina diftericaInfo
- Publication number
- AR086914A1 AR086914A1 ARP120102087A ARP120102087A AR086914A1 AR 086914 A1 AR086914 A1 AR 086914A1 AR P120102087 A ARP120102087 A AR P120102087A AR P120102087 A ARP120102087 A AR P120102087A AR 086914 A1 AR086914 A1 AR 086914A1
- Authority
- AR
- Argentina
- Prior art keywords
- diphtheria toxin
- separating agent
- mutant
- hydroxyapatite
- agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 238000000746 purification Methods 0.000 title abstract 3
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 12
- 102000016607 Diphtheria Toxin Human genes 0.000 abstract 8
- 108010053187 Diphtheria Toxin Proteins 0.000 abstract 8
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract 6
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 238000000926 separation method Methods 0.000 abstract 3
- 239000012535 impurity Substances 0.000 abstract 2
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000005194 fractionation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000012433 multimodal chromatography Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere al uso de cromatografía de hidroxiapatita y cromatografía multimodal para la purificación de la toxina diftérica, o una forma mutante del mismo, de una mezcla, por ejemplo, una mezcla de fermentación en célula huésped que contiene impurezas, tales como proteínas y ADN de la célula huésped. La presente se refiere además a la integración de dicho procedimiento en un procedimiento de múltiples etapas con otros procedimientos de fraccionamiento para la purificación de la toxina diftérica adecuados para aplicaciones in vitro e in vivo.Reivindicación 1: Un procedimiento de purificar la toxina diftérica, o un mutante de la misma, de una mezcla que contiene la toxina diftérica, o una forma mutante de la misma, que comprende: a) poner en contacto la mezcla con un primer agente de separación en condiciones tales que la toxina diftérica, o un mutante de la misma, se une al primer agente de separación; b) eluir la toxina diftérica, o un mutante de la misma, del primer agente de separación; c) poner en contacto el material eluido obtenido en la tapa a) con un segundo agente de separación en condiciones tales que la toxina diftérica, o un mutante de la misma, se une al segundo agente de separación; y d) eluir dicha toxina diftérica, o un mutante de la misma, del segundo agente de separación; en el que 1) el primer agente de separación es hidroxiapatita y el segundo agente de separación es una resma multimodal; o 2) el primer agente de separación es resina multimodal y el segundo agente de separación es hidroxiapatita; y cuando el primer agente de separación o el segundo agente de separación es hidroxiapatita, antes de eluir de la hidroxiapatita, la hidroxiapatita sufre una etapa de lavado en condiciones tales que se eliminan las impurezas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496276P | 2011-06-13 | 2011-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086914A1 true AR086914A1 (es) | 2014-01-29 |
Family
ID=47357422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102087A AR086914A1 (es) | 2011-06-13 | 2012-06-12 | Procedimientos de purificacion de formas nativas o mutantes de la toxina difterica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140193876A1 (es) |
| EP (1) | EP2718306A1 (es) |
| KR (1) | KR20140038517A (es) |
| CN (1) | CN103732610A (es) |
| AR (1) | AR086914A1 (es) |
| BR (1) | BR112013032225A2 (es) |
| MX (1) | MX2013014773A (es) |
| TW (1) | TW201309722A (es) |
| WO (1) | WO2012173876A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188242B2 (en) * | 2008-04-08 | 2012-05-29 | Bio-Rad Laboratories, Inc. | Chromatography purification of antibodies |
| US9029517B2 (en) | 2010-07-30 | 2015-05-12 | Emd Millipore Corporation | Chromatography media and method |
| US20140228539A1 (en) * | 2011-10-21 | 2014-08-14 | Tanvex Biologics Corp. | Separation of acetylated proteins from unacetylated proteins |
| CN105777862A (zh) * | 2012-10-24 | 2016-07-20 | 建新公司 | 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子 |
| CN103266125A (zh) * | 2013-06-04 | 2013-08-28 | 北京民海生物科技有限公司 | 白喉毒素突变体crm197的制备方法 |
| US10329323B2 (en) | 2014-07-25 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method for purifying antibodies using PBS |
| US20170298091A1 (en) | 2014-12-08 | 2017-10-19 | Emd Millipore Corporation | Mixed Bed Ion Exchange Adsorber |
| MX2018005831A (es) * | 2015-11-18 | 2018-08-01 | Merck Patent Gmbh | Gradientes de ph-sal opuestos para separaciones de proteina mejoradas. |
| EP3519351B1 (en) | 2016-09-29 | 2025-04-30 | Bio-Rad Laboratories, Inc. | Protein-nanoparticle conjugate purification methods |
| KR20240169144A (ko) | 2017-01-31 | 2024-12-02 | 머크 샤프 앤드 돔 엘엘씨 | 다당류-단백질 접합체 제조 방법 |
| EP3576759B1 (en) | 2017-01-31 | 2025-09-24 | Merck Sharp & Dohme LLC | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
| CN107043431B (zh) * | 2017-02-23 | 2020-06-30 | 上海瑞宙生物科技有限公司 | 细菌性荚膜多糖的纯化方法 |
| PT3585803T (pt) | 2017-02-24 | 2025-12-22 | Merck Sharp & Dohme | Formulações de vacina pneumocócica conjugada |
| US11174284B2 (en) * | 2017-04-04 | 2021-11-16 | Scarab Genomics, Llc | Purification of CRM 197 from bacteria |
| CN107163111A (zh) * | 2017-06-15 | 2017-09-15 | 华兰生物工程股份有限公司 | 纯化白喉毒素的方法 |
| US20210130396A1 (en) * | 2017-08-30 | 2021-05-06 | Ares Trading S.A. | Method for purifying proteins |
| FI3678654T3 (fi) | 2017-09-07 | 2024-09-02 | Merck Sharp & Dohme Llc | Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa |
| AU2018400751B2 (en) | 2017-12-06 | 2022-07-21 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2019178587A1 (en) * | 2018-03-16 | 2019-09-19 | Bio-Rad Laboratories, Inc. | Purification of target molecules |
| GEAP202415690A (en) | 2018-12-19 | 2024-01-10 | Merck Sharp & Dohme Llc | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| GB201910697D0 (en) * | 2019-07-26 | 2019-09-11 | Binding Site Group Ltd | Lonisation control |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| CN112851775B (zh) * | 2021-02-07 | 2022-02-18 | 艾美卫信生物药业（浙江）有限公司 | 一种白喉毒素无毒突变体crm197蛋白、生产方法以及应用 |
| CN115197311B (zh) * | 2021-04-09 | 2024-10-22 | 康立泰生物医药(青岛)有限公司 | 一种重组人白介素12蛋白的纯化方法 |
| EP4682254A1 (en) * | 2023-03-16 | 2026-01-21 | Daewoong Co., Ltd. | Improved method of purifying botulinum toxin using multimodal chromatography |
| TW202500153A (zh) | 2023-05-18 | 2025-01-01 | 美商默沙東有限責任公司 | 用於肺炎鏈球菌疫苗之化合物及佐劑調配物 |
| WO2025174398A1 (en) | 2024-02-14 | 2025-08-21 | Merck Sharp & Dohme Llc | 26-valent pneumococcal conjugate vaccines and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004532611A (ja) * | 2000-11-28 | 2004-10-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１９ |
| WO2005080556A2 (en) * | 2004-02-23 | 2005-09-01 | Crucell Holland B.V. | Virus purification methods |
| JP2010515917A (ja) * | 2007-01-10 | 2010-05-13 | ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー | クロマトグラフィーレジン |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
-
2012
- 2012-06-08 EP EP12800460.3A patent/EP2718306A1/en not_active Withdrawn
- 2012-06-08 BR BR112013032225A patent/BR112013032225A2/pt not_active IP Right Cessation
- 2012-06-08 US US14/125,695 patent/US20140193876A1/en not_active Abandoned
- 2012-06-08 MX MX2013014773A patent/MX2013014773A/es not_active Application Discontinuation
- 2012-06-08 KR KR1020147000714A patent/KR20140038517A/ko not_active Withdrawn
- 2012-06-08 CN CN201280039610.1A patent/CN103732610A/zh active Pending
- 2012-06-08 WO PCT/US2012/041444 patent/WO2012173876A1/en not_active Ceased
- 2012-06-12 AR ARP120102087A patent/AR086914A1/es not_active Application Discontinuation
- 2012-06-13 TW TW101121030A patent/TW201309722A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2718306A1 (en) | 2014-04-16 |
| US20140193876A1 (en) | 2014-07-10 |
| BR112013032225A2 (pt) | 2016-08-16 |
| KR20140038517A (ko) | 2014-03-28 |
| CN103732610A (zh) | 2014-04-16 |
| TW201309722A (zh) | 2013-03-01 |
| MX2013014773A (es) | 2014-01-20 |
| WO2012173876A1 (en) | 2012-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086914A1 (es) | Procedimientos de purificacion de formas nativas o mutantes de la toxina difterica | |
| Spohner et al. | Kluyveromyces lactis: an emerging tool in biotechnology | |
| EA201070987A1 (ru) | Очищенные гибридные белки иммуноглобулина и способы их очищения | |
| WO2017031476A3 (en) | Purification of fkpa and uses thereof for producing recombinant polypeptides | |
| CY1121519T1 (el) | Καθαρισμος της υδουρονικης-2-σουλφατασης | |
| PE20181316A1 (es) | Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer | |
| IN2012DN00363A (es) | ||
| PE20190434A1 (es) | PROCESO DE PRODUCCION DE rAAV A BASE DE COLUMNAS COMPLETAMENTE ESCALABLE | |
| WO2013028330A3 (en) | Methods of reducing level of one of more impurities in a sample during protein purification | |
| PE20120543A1 (es) | Anticuerpo anti-tau ps422 | |
| MX371442B (es) | VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB. | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
| WO2010147686A3 (en) | Methods of purifying small modular immunopharmaceutical proteins | |
| MX2015005178A (es) | Purificacion de polipeptidos usando ultrafiltracion de flujo tangencial de etapa doble. | |
| EA201590810A1 (ru) | Композиция эмульгатора, содержащего фосфолипиды | |
| WO2011021194A3 (en) | Pericyte progenitor cells and methods of generating and using same | |
| WO2010151632A8 (en) | Protein purification by caprylic acid (octanoic acid ) precipitation | |
| MX2019000903A (es) | Metodos para purificar proteinas que contienen fc. | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| EA200801813A1 (ru) | Содержащие жирные кислоты побочные продукты и способы их применения | |
| WO2019234614A3 (en) | A process for the separation and purification of phycobiliproteins | |
| WO2009130296A3 (en) | Anti-alk1 antibodies and uses thereof | |
| IN2012DN00879A (es) | ||
| WO2012066569A8 (en) | A novel process for the purification of tissue plasminogen activator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |